Möchten Sie immer auf dem neuesten Stand bleiben?

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA® (tocilizumab)Biosimilars have the potential...

TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients' individual preferences and needs The subcutaneous option...

The innovative and scalable gene therapy manufacturing facility will support Biogen’s plan to advance its gene therapy portfolioThe new facility is expected to employ approximately 90 people and to be...

$170,000 grants will fill critical gap for 3,000 food insecure families in Greater Boston via Food For Free’s new grocery box program CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Life...

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the expiration date results of its previously announced offer to purchase for cash (the...

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the expiration date results of its previously announced private offer to exchange (the...

Golden Tickets winners Bolden Therapeutics and Seranova Bio will have access to a state-of-the-art lab facilities at LabCentral with mentorship and support from Biogen CAMBRIDGE, Mass., Feb. 11,...

CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the pricing terms of its previously announced offer to purchase for cash (the “Cash Offer”)...

CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the pricing terms of its previously announced private offer to exchange (the “Exchange...

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the commencement of an offer to purchase for cash (the “Cash Offer”) any and all of its...